For the year ending 2025-12-31, BIAFW made $6,161,959 in revenue. -$14,909,754 in net income. Net profit margin of -241.96%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Net revenue | 6,161,959 | |||
| Direct costs and expenses | 4,226,799 | |||
| Research and development | 1,383,359 | |||
| Clinical development | 705,744 | |||
| Selling, general and administrative | 9,913,729 | |||
| Depreciation and amortization | 504,836 | |||
| Total operating expenses | 16,734,467 | |||
| Loss from operations | -10,572,508 | |||
| Interest income | 23,385 | |||
| Interest expense | 44,372 | |||
| Other income | 40,490 | |||
| Other expense | 502,429 | |||
| Change in fair value of warrants issued | 3,810,278 | |||
| Loss before income tax expense | -14,865,712 | |||
| Income tax expense | 44,042 | |||
| Net loss | -14,909,754 | |||
| Basic EPS | -8.66 | |||
| Diluted EPS | -8.66 | |||
| Basic Average Shares | 1,721,082 | |||
| Diluted Average Shares | 1,721,082 | |||
bioAffinity Technologies, Inc. (BIAFW)
bioAffinity Technologies, Inc. (BIAFW)